



CBS Control #: CBS6783 HPFB File #: C1892-100390 REF: H-2324-BRMPDC

Supriya Rave Regulatory Compliance & Enforcement Specialist **Biological Product Compliance Program** Regulatory Operations and Enforcement Branch Health Canada 180 Queen Street West, 10th Floor Toronto, ON M5V 3L7

Canadian BLOOD PLASMA STEM CELLS

Dear Supriya:

Re: Responses to Health Canada Inspection of Licensed Activities at **Brampton Plasma Donor Centre** 2023-10-23 to 2023-10-27

The following are the actions undertaken by Canadian Blood Services in response to the observations contained in the Health Canada Exit Notice dated 2023-11-16.

Section 39 - Donor Suitability Assessment

- 1. For donation C070923302376006, clinic date May 23, 2023 (clinic PT001), the following were observed:
 - a) The Technical Questionnaire Phlebotomy stated '<=25 mL No deferral' for question 7B ('RBC Loss'). However, as per WI 01275, Collect Product – Plasma Program (Revision 4), because this donation was a routine non-saline procedure and a red blood cell loss of 26-50 mL, a 2 week deferral (P014) was required. This donor was not deferred for 2 weeks.

It is acknowledged that up to the time of inspection, this donor had only made one donation.

It was confirmed following the inspection that the unit in question was part of Dev-23-007954 that was initiated on 2023-09-20 for missed deferrals identified prior to the inspection at Brampton Plasma Donor Centre. The corrective action included the review of WI-01275 Collect Product – Plasma Program with staff prior to the closure of the deviation on 2023-10-04.

Following the inspection, a huddle note outlining the steps to be followed in WI-01275 Collect Product - Plasma Program regarding calculating red blood cell loss was read and signed by all staff. This was completed by 2023-11-20.



b) On the PDC Source Plasma Anticoagulant and Saline Documentation form – Plasma Program, initials were recorded under the column 'Solutions, Connections Verified & Collection Started By: (initials)' for saline. However, a 'NA' should have been recorded because saline was not administered during this donation.

MQE-23-003690 was initiated on 2023-10-25.

All staff read and signed the huddle note on the correct documentation required as per F801408 PDC Source Plasma Anticoagulant and Saline Documentation Form – Plasma Program when performing solution checks. This was completed by 2023-11-20.

<u>Section 95 – Operating Procedures</u>

2. On the Quality Inspection of Critical Supplies record for a Collect Separation Bowl 625B, Lot # 2303003C shipment received on 2023/05/02 and accepted on 2023/05/04, the comments section in section 2 did not have the proper documentation for the inspection of the outer packaging. This is contrary to WI 00773, Inspection of Critical Supplies (Revision 1), Section 4, Step 4.

DEV-23-009865 was initiated on 2023-11-20.

Team Leads, Managers and Plasma Associates – Process Leads completed a read and sign huddle note regarding following the instructions in step 4 of WI-00773 Inspection of Critical Supplies (Revision 2) for the documentation requirements of the Outer Shipment Conditions in Section 2 of the Critical Supplies form.

If you require clarification or further information, please do not hesitate to contact the undersigned. Please reference the above CBS control number in any correspondence.

Sincerely,

Clustran Choquet

Dr. Christian Choquet

Vice-President